Skye Bioscience, Inc. - Common Stock — Quarterly Financial Statistics (NASDAQ:SKYE) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -9.19 M-10.75 M-13.36 M-9.77 M-8.56 M -42.43 M Cash from investing activities -12.81 M-11.86 M7.97 M-2.8 M10.9 M 4.2 M Cash from financing activities 018.16 K011.41 K-71.53 K -41.95 K Free cash flow -9.19 M-10.75 M-13.36 M-9.77 M-8.56 M -42.43 M

News

Cantor Fitzgerald reiterates Skye Bioscience stock rating at Neutral

Citizens reiterates Skye Bioscience stock rating on weight loss data

Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript

Skye Q4 2025 slides: nimacimab combination shows 3% added weight loss

H.C. Wainwright reiterates Buy rating on Skye Bioscience stock at $20

Penny Stock Skye Bioscience Drug Combo With Wegovy Shows Over 22% Weight Loss After One Year - Skye Bioscience (NASDAQ:SKYE)

Nimacimab-semaglutide combo shows 22.3% weight loss at 52 weeks

Skye Bioscience reports positive results for obesity drug nimacimab

Cantor Fitzgerald maintains Neutral rating on Skye Bioscience stock

Skye Bioscience to report CBeyond extension data in Q1, plans Phase 2b trial

Citizens reiterates Market Outperform rating on Skye Bioscience stock

Skye Bioscience stock jumps after Halozyme collaboration for obesity drug